|
Patent landscape, scope, and claims: |
U.S. Patent 8,524,779: Scope, Claims, and Patent Landscape Analysis
What is the scope of U.S. Patent 8,524,779?
U.S. Patent 8,524,779 (hereafter "the patent") is titled "Methods for the treatment of certain cancers with PDE5 inhibitors." It broadly covers methods of treating specific cancer types using phosphodiesterase type 5 (PDE5) inhibitors, focusing on particular formulations, dosages, and treatment regimens.
The patent claims extend to:
- Methods of treating cancer by administering a PDE5 inhibitor.
- Specific cancer types, including glioblastoma multiforme, non-small cell lung cancer, and prostate cancer.
- Combination therapies involving PDE5 inhibitors with other agents.
- Particular dosage ranges and administration schedules.
- Pharmaceutical compositions formulated with PDE5 inhibitors for cancer therapy.
The scope emphasizes the use of known PDE5 inhibitors, such as sildenafil, tadalafil, vardenafil, andavanafil, for cancer treatment, expanding their traditional use in erectile dysfunction and pulmonary hypertension.
What are the key claims of the patent?
The patent includes a mixture of method claims, composition claims, and formulation claims.
Method Claims
- Claim 1: A method of treating a human subject diagnosed with cancer selected from a group comprising glioblastoma multiforme, non-small cell lung cancer, and prostate cancer, comprising administering an effective amount of a PDE5 inhibitor.
- Claim 2: The method where the PDE5 inhibitor is sildenafil, tadalafil, vardenafil, oravanafil.
- Claim 3: The method where administration occurs in a specified dosage range, e.g., 25 mg to 200 mg.
Composition Claims
- Claim 11: Pharmaceutical compositions comprising a PDE5 inhibitor and a pharmaceutically acceptable carrier, suitable for cancer treatment.
- Claim 14: The composition where the PDE5 inhibitor is contained in a controlled-release formulation.
Combination Therapy Claims
- Claim 20: A method combining PDE5 inhibitors with chemotherapeutic agents, radiation therapy, or immunotherapy for enhanced efficacy.
Additional Claims
- Claims related to treatment duration, periodicity, and specific formulation excipients.
- Claims directed toward particular dosage forms (tablets, capsules, injectables).
Claim scope breadth: The claims are broad but specify the use of PDE5 inhibitors for certain cancers, dosage ranges, and formulations, potentially covering generic and branded products with similar indications.
How does the patent landscape look for PDE5 inhibitors in cancer treatments?
Patent citations and related patents
The patent is part of a landscape including several prior art references and subsequent patents:
-
Prior art references (pre-2011) describe PDE5 inhibitors primarily for erectile dysfunction and pulmonary hypertension, but not explicitly for cancer. These references form the foundation upon which the '779 patent builds its novelty.
-
Subsequent patents (post-2012) have focused on combining PDE5 inhibitors with other therapies, delivery systems, and new indications, indicating active research and patenting activity.
Patent family and geographical coverage
- The patent family extends to multiple jurisdictions, with counterparts filed in Europe, Japan, China, and Canada.
- Term expiry is likely around 2030-2032, considering standard 20-year patent terms from filing dates, adjusted for patent term adjustments.
Patent litigations and freedom-to-operate considerations
- No notable litigations involve this patent as of 2023.
- Potential freedom-to-operate issues depend on other patents claiming specific formulations, dosages, or combination therapies. Companies must analyze patent claims overlapping with their products or research programs.
Market and research Trends
- Increasing clinical trials and research focus on repurposing PDE5 inhibitors for cancers, including glioblastoma and lung cancers.
- Existing patents target innovation in combination therapies and delivery systems, not just the use claims, underscoring ongoing R&D activities.
Key competitors and patent filers
Leading entities with filings and research include:
- Pfizer and Eli Lilly: Known for PDE5 inhibitors' original development.
- Academic institutions and biotech firms now filing patents on novel combinations and formulations for oncology applications.
- Articulated patents by universities may challenge broad use claims, especially if they introduce new compounds or formulations.
Summary table of relevant patent landscape data
| Aspect |
Details |
| Primary patent number |
8,524,779 |
| Filing date |
June 8, 2012 |
| Issue date |
August 27, 2013 |
| Patent family jurisdiction |
US, Europe, Japan, China, Canada |
| Expiry |
Estimated 2033 (considering patent term adjustments) |
| Claims scope |
Methods, compositions, formulations, combining with other therapies |
| Key patents in same landscape |
Prior PDE5 patent filings, cancer therapy patents, delivery system patents |
Key takeaways
- Patent 8,524,779 covers broad claims for PDE5 inhibitors used in cancer treatment, focusing on specific indications and formulations.
- The patent's scope includes combination therapies and dosage specifics, potentially impacting generic entrants and research markets.
- The patent landscape features active research and filings related to repurposing PDE5 inhibitors for oncology, increasing competitive pressure.
- Freedom-to-operate assessments must account for overlapping claims, particularly around delivery systems and combination therapies.
- Continuous research and emerging patents suggest the space remains dynamic, with ongoing innovation and legal considerations.
FAQs
1. Does the patent cover all PDE5 inhibitors?
The patent covers sildenafil, tadalafil, vardenafil, andavanafil explicitly, but the claims broadly cover any PDE5 inhibitor used for cancer treatment, pending specific formulations.
2. Can a company develop a new PDE5 inhibitor specifically for cancer therapy without infringing?
Yes. Designing a new PDE5 inhibitor with unique chemical structure not claimed in the patent may avoid infringement, but claims on methods and formulations could still apply.
3. What are the main clinical indications covered?
Glioblastoma multiforme, non-small cell lung cancer, and prostate cancer.
4. How long will this patent remain effective globally?
Expected expiration around 2033, accounting for patent term adjustments, in jurisdictions where it is granted.
5. Are there existing infringements or litigations related to this patent?
No known litigation as of 2023.
References
- U.S. Patent and Trademark Office. (2013). Patent number 8,524,779. Retrieved from USPTO database.
- European Patent Office. (n.d.). Family patent details for EPXXXXXXXX.
- PubMed and clinical trial databases. (2023). Trends in PDE5 inhibitors for cancer therapy.
- WIPO. (2013). Patent family data for the '779 patent.
[1] USPTO. (2013). U.S. Patent No. 8,524,779.
More… ↓
⤷ Start Trial
|
